{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:20:39Z","timestamp":1790626839972,"version":"4.1.0"},"reference-count":157,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pacific Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.apjo.2026.100302","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:20:15Z","timestamp":1772900415000},"page":"100302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advancing perspectives on proliferative vitreoretinopathy: Updates in experimental research and emerging clinical treatments"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4618-8155","authenticated-orcid":false,"given":"Fang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8708-4694","authenticated-orcid":false,"given":"Elie","family":"Motulsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz","family":"Roisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6315-2077","authenticated-orcid":false,"given":"Kanae","family":"Fukutsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chee Wai","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veluchamy Amutha","family":"Barathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.H.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9106-6416","authenticated-orcid":false,"given":"Leo A.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin SW","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib1","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00417-023-06264-1","article-title":"Proliferative vitreoretinopathy: an update on the current and emerging treatment options","volume":"262","author":"Ferro Desideri","year":"2024","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib2","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12886-016-0390-2","article-title":"Anatomical success rate of pars plana vitrectomy for treatment of complex rhegmatogenous retinal detachment","volume":"16","author":"Lumi","year":"2016","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib3","article-title":"Rhegmatogenous retinal detachment: a review of current practice in diagnosis and management","volume":"5","author":"Sultan","year":"2020","journal-title":"BMJ Open Ophthalmol"},{"issue":"5","key":"10.1016\/j.apjo.2026.100302_bib4","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/IAE.0000000000004391","article-title":"Risk factors for proliferative vitreoretinopathy in a large clinical database","volume":"45","author":"Oncel","year":"2025","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.apjo.2026.100302_bib5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1001\/jamaophthalmol.2025.1851","article-title":"Long-term cannabis use and risk of postoperative proliferative vitreoretinopathy","volume":"143","author":"Alshaikhsalama","year":"2025","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100302_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.oret.2023.09.011","article-title":"Surgical outcomes of rhegmatogenous retinal detachment and fellow eye involvement in adolescent and young adult patients","volume":"8","author":"Bomdica","year":"2024","journal-title":"Ophthalmol Retin"},{"issue":"2","key":"10.1016\/j.apjo.2026.100302_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0002-9394(14)76695-4","article-title":"An updated classification of retinal detachment with proliferative vitreoretinopathy","volume":"112","author":"Machemer","year":"1991","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.apjo.2026.100302_bib8","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.oret.2023.07.009","article-title":"Primary Retinal Detachment Repair in Eyes Deemed High Risk for Proliferative Vitreoretinopathy: Surgical Outcomes in 389 Eyes","volume":"7","author":"Salabati","year":"2023","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.apjo.2026.100302_bib9","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/978-3-031-76550-6_32","article-title":"Effect of Photobiomodulation on Proliferative Changes in the Retina: Evidence from an In Vitro Model of PVR","volume":"1468","author":"Watson","year":"2025","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.apjo.2026.100302_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2022.109170","article-title":"Cell culture models to study retinal pigment epithelium-related pathogenesis in age-related macular degeneration","volume":"222","author":"Bharti","year":"2022","journal-title":"Exp Eye Res"},{"issue":"8","key":"10.1016\/j.apjo.2026.100302_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cells12081155","article-title":"IKKbeta Inhibition Attenuates Epithelial Mesenchymal Transition of Human Stem Cell-Derived Retinal Pigment Epithelium","volume":"12","author":"Sripathi","year":"2023","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.apjo.2026.100302_bib12","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1167\/iovs.16-20912","article-title":"Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy","volume":"58","author":"Amarnani","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.apjo.2026.100302_bib13","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db08-0302","article-title":"Potent inhibition of cicatricial contraction in proliferative vitreoretinal diseases by statins","volume":"57","author":"Kawahara","year":"2008","journal-title":"Diabetes"},{"issue":"45","key":"10.1016\/j.apjo.2026.100302_bib14","doi-asserted-by":"crossref","first-page":"17504","DOI":"10.1073\/pnas.0804054105","article-title":"Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target","volume":"105","author":"Kita","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77254-0","article-title":"Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy","volume":"10","author":"Delgado-Tirado","year":"2020","journal-title":"Sci Rep"},{"issue":"775","key":"10.1016\/j.apjo.2026.100302_bib16","article-title":"An mRNA-encoded dominant-negative inhibitor of transcription factor RUNX1 suppresses vitreoretinal disease in experimental models","volume":"16","author":"O'Hare","year":"2024","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.apjo.2026.100302_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054509","article-title":"Experimental models to study epithelial-mesenchymal transition in proliferative vitreoretinopathy","volume":"24","author":"Datlibagi","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.apjo.2026.100302_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/tvst.9.7.9","article-title":"A mouse model of proliferative vitreoretinopathy induced by intravitreal injection of gas and RPE cells","volume":"9","author":"Heffer","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"9","key":"10.1016\/j.apjo.2026.100302_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1167\/tvst.9.9.46","article-title":"Endogenous or Exogenous Retinal Pigment Epithelial Cells: A Comparison of Two Experimental Animal Models of Proliferative Vitreoretinopathy","volume":"9","author":"Wong","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"6","key":"10.1016\/j.apjo.2026.100302_bib20","first-page":"2001","article-title":"Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy","volume":"43","author":"Mori","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.apjo.2026.100302_bib21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/jcp.20583","article-title":"Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies","volume":"207","author":"Akiyama","year":"2006","journal-title":"J Cell Physiol"},{"issue":"3-4","key":"10.1016\/j.apjo.2026.100302_bib22","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000371901","article-title":"The Effects of Ozurdex(R) (Dexamethasone Intravitreal Implant) on Experimental Proliferative Vitreoretinopathy","volume":"233","author":"Kuo","year":"2015","journal-title":"Ophthalmologica"},{"issue":"12","key":"10.1016\/j.apjo.2026.100302_bib23","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1167\/iovs.17-22045","article-title":"Introduction of the MDM2 T309G Mutation in Primary Human Retinal Epithelial Cells Enhances Experimental Proliferative Vitreoretinopathy","volume":"58","author":"Zhou","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-51633-8","article-title":"Characterisation of the inflammatory cytokine and growth factor profile in a rabbit model of proliferative vitreoretinopathy","volume":"9","author":"Wong","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.apjo.2026.100302_bib25","first-page":"731","article-title":"Effect of etanercept on post-traumatic proliferative vitreoretinopathy","volume":"12","author":"Chen","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100302_bib26","article-title":"Vitreous Olink proteomics reveals inflammatory biomarkers for diagnosis and prognosis of traumatic proliferative vitreoretinopathy","volume":"15","author":"Guo","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/glia.22942","article-title":"Muller glia as an important source of cytokines and inflammatory factors present in the gliotic retina during proliferative vitreoretinopathy","volume":"64","author":"Eastlake","year":"2016","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/112067219700700112","article-title":"Levels of some cytokines in subretinal fluid in proliferative vitreoretinopathy and rhegmatogenous retinal detachment","volume":"7","author":"Kenarova","year":"1997","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"10.1016\/j.apjo.2026.100302_bib29","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1167\/iovs.14-14818","article-title":"The role of thrombin in proliferative vitreoretinopathy","volume":"55","author":"Bastiaans","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.apjo.2026.100302_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cyto.2014.02.012","article-title":"Comparison of interleukin-6 and matrix metalloproteinase expression in the subretinal fluid and the vitreous during proliferative vitreoretinopathy: correlations with extent, duration of RRD and PVR grade","volume":"67","author":"Symeonidis","year":"2014","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12974-017-0886-6","article-title":"Rapid monocyte infiltration following retinal detachment is dependent on non-canonical IL6 signaling through gp130","volume":"14","author":"Wang","year":"2017","journal-title":"J Neuroinflamm"},{"issue":"6","key":"10.1016\/j.apjo.2026.100302_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00418-020-01923-4","article-title":"Interleukin-6 promotes migration and extracellular matrix synthesis in retinal pigment epithelial cells","volume":"154","author":"Qi","year":"2020","journal-title":"Histochem Cell Biol"},{"issue":"11","key":"10.1016\/j.apjo.2026.100302_bib33","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/bjo.83.11.1296","article-title":"Detection of cytokine mRNA production in infiltrating cells in proliferative vitreoretinopathy using reverse transcription polymerase chain reaction","volume":"83","author":"El-Ghrably","year":"1999","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100302_bib34","first-page":"140","article-title":"[TNF-alpha, IL-8 and IL-6 in the early inflammatory stage of experimental PVR model induced by macrophages]","volume":"35","author":"Hui","year":"1999","journal-title":"Zhonghua Yan Ke Za Zhi"},{"issue":"11","key":"10.1016\/j.apjo.2026.100302_bib35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3109\/02713689409025133","article-title":"Distribution of cytokine proteins within epiretinal membranes in proliferative vitreoretinopathy","volume":"13","author":"Limb","year":"1994","journal-title":"Curr Eye Res"},{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib36","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1167\/iovs.12-10931","article-title":"A genetic case-control study confirms the implication of SMAD7 and TNF locus in the development of proliferative vitreoretinopathy","volume":"54","author":"Rojas","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.apjo.2026.100302_bib37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s42003-019-0406-6","article-title":"P38 inhibition reverses TGFbeta1 and TNFalpha-induced contraction in a model of proliferative vitreoretinopathy","volume":"2","author":"Schiff","year":"2019","journal-title":"Commun Biol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib38","doi-asserted-by":"crossref","first-page":"22","DOI":"10.18240\/ijo.2023.01.04","article-title":"Intravitreal slow-release dexamethasone alleviates traumatic proliferative vitreoretinopathy by inhibiting persistent inflammation and Muller cell gliosis in rabbits","volume":"16","author":"Zhao","year":"2023","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100302_bib39","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1146\/annurev.biochem.67.1.753","article-title":"TGF-beta signal transduction","volume":"67","author":"Massague","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.apjo.2026.100302_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2025.149338","article-title":"Crosstalk between signaling pathways (Rho\/ROCK, TGF-beta and Wnt\/beta-Catenin Pathways\/ PI3K-AKT-mTOR) in Cataract: A Mechanistic Exploration and therapeutic strategy","volume":"947","author":"Khan","year":"2025","journal-title":"Gene"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/08977199009037500","article-title":"Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3","volume":"3","author":"Brown","year":"1990","journal-title":"Growth Factors"},{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/exer.1994.1114","article-title":"Transforming growth factor beta 2 is the predominant isoform in the neural retina, retinal pigment epithelium-choroid and vitreous of the monkey eye","volume":"59","author":"Pfeffer","year":"1994","journal-title":"Exp Eye Res"},{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib43","first-page":"477","article-title":"Heterogeneity in localization of isoforms of TGF-beta in human retina, vitreous, and choroid","volume":"34","author":"Lutty","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2337\/db06-0581","article-title":"Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor","volume":"56","author":"Kita","year":"2007","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.apjo.2026.100302_bib45","first-page":"2336","article-title":"TGF-beta1, TGF-beta receptor II and ED-A fibronectin expression in myofibroblast of vitreoretinopathy","volume":"41","author":"Bochaton-Piallat","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.apjo.2026.100302_bib46","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1167\/iovs.03-1330","article-title":"The involvement of the rho-kinase pathway and its regulation in cytokine-induced collagen gel contraction by hyalocytes","volume":"45","author":"Hirayama","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1167\/iovs.62.4.21","article-title":"Effectively Intervening Epithelial-Mesenchymal Transition of Retinal Pigment Epithelial Cells With a Combination of ROCK and TGF-beta Signaling Inhibitors","volume":"62","author":"Chen","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.apjo.2026.100302_bib48","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.eye.6702169","article-title":"Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy","volume":"21","author":"Cui","year":"2007","journal-title":"Eye (Lond)"},{"issue":"5","key":"10.1016\/j.apjo.2026.100302_bib49","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1167\/iovs.06-0965","article-title":"A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy","volume":"48","author":"Lei","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1167\/iovs.07-0776","article-title":"Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy","volume":"49","author":"Lei","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.apjo.2026.100302_bib51","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1167\/iovs.08-3042","article-title":"Growth factors outside the PDGF family drive experimental PVR","volume":"50","author":"Lei","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12041259","article-title":"Vitreal Concentrations of Vascular Endothelial Growth Factor in Patients with Rhegmatogenous Retinal Detachment","volume":"12","author":"Hasanpour","year":"2023","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.apjo.2026.100302_bib53","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1007\/s12325-020-01325-x","article-title":"Distinct Serum and Vitreous Inflammation-Related Factor Profiles in Patients with Proliferative Vitreoretinopathy","volume":"37","author":"Ni","year":"2020","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000324200","article-title":"Vitreous vascular endothelial growth factor concentrations in proliferative diabetic retinopathy versus proliferative vitreoretinopathy","volume":"47","author":"Citirik","year":"2012","journal-title":"Ophthalmic Res"},{"issue":"11","key":"10.1016\/j.apjo.2026.100302_bib55","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1016\/j.ajpath.2014.07.026","article-title":"Vascular endothelial growth factor acts primarily via platelet-derived growth factor receptor alpha to promote proliferative vitreoretinopathy","volume":"184","author":"Pennock","year":"2014","journal-title":"Am J Pathol"},{"issue":"18","key":"10.1016\/j.apjo.2026.100302_bib56","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1128\/MCB.01019-15","article-title":"Vascular endothelial cell growth factor A acts via platelet-derived growth factor receptor alpha to promote viability of cells enduring hypoxia","volume":"36","author":"Pennock","year":"2016","journal-title":"Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.apjo.2026.100302_bib57","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/j.ajpath.2013.01.052","article-title":"Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease","volume":"182","author":"Pennock","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.apjo.2026.100302_bib58","article-title":"The Role of Intravitreal Anti-VEGF Agents in Rabbit Eye Model of Open-Globe Injury","volume":"2021","author":"Zhao","year":"2021","journal-title":"J Ophthalmol"},{"issue":"9","key":"10.1016\/j.apjo.2026.100302_bib59","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jfo.2021.04.007","article-title":"Vitreous cytokine expression profiles in patients with retinal detachment","volume":"44","author":"Conart","year":"2021","journal-title":"J Fr Ophtalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib60","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-03294-9","article-title":"Postoperative proliferative vitreoretinopathy development is linked to vitreal CXCL5 concentrations","volume":"11","author":"Zandi","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.apjo.2026.100302_bib61","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/bjo.84.5.506","article-title":"Risk factors for proliferative vitreoretinopathy after primary vitrectomy: a prospective study","volume":"84","author":"Kon","year":"2000","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.apjo.2026.100302_bib62","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/S0161-6420(01)00553-X","article-title":"How to predict proliferative vitreoretinopathy: a prospective study","volume":"108","author":"Asaria","year":"2001","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.apjo.2026.100302_bib63","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ophtha.2024.01.032","article-title":"Association of Cutaneous Keloids, Hypertrophic Scarring, and Fibrosis with Risk of Postoperative Proliferative Vitreoretinopathy","volume":"131","author":"Mammo","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2026.100302_bib64","article-title":"Case series: Two cases of severe retinal cicatricial contraction after vitrectomy for open-globe injury in patients with skin keloid","volume":"25","author":"Liao","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"10","key":"10.1016\/j.apjo.2026.100302_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0292698","article-title":"Risk factors for proliferative vitreoretinopathy after retinal detachment surgery: A systematic review and meta-analysis","volume":"18","author":"Xiang","year":"2023","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.apjo.2026.100302_bib66","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1167\/iovs.08-2670","article-title":"Development of predictive models of proliferative vitreoretinopathy based on genetic variables: the Retina 4 project","volume":"50","author":"Rojas","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.apjo.2026.100302_bib67","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.oret.2024.06.007","article-title":"Risk of Proliferative Vitreoretinopathy in the Second Eye in Adult Patients with Bilateral Retinal Detachment","volume":"8","author":"Shepherd","year":"2024","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib68","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/IAE.0b013e3182173753","article-title":"Anterior chamber aqueous flare is a strong predictor for proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment","volume":"32","author":"Schroder","year":"2012","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib69","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1111\/aos.13254","article-title":"Validity of aqueous flare measurement in predicting proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment","volume":"95","author":"Conart","year":"2017","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib70","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/bjophthalmol-2012-302636","article-title":"Profibrotic cytokines in aqueous humour correlate with aqueous flare in patients with rhegmatogenous retinal detachment","volume":"97","author":"Hoerster","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.apjo.2026.100302_bib71","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1080\/08164622.2022.2133596","article-title":"Predictive values of systemic inflammation biomarkers in proliferative vitreoretinopathy associated with primary rhegmatogenous retinal detachment","volume":"106","author":"Kocak","year":"2023","journal-title":"Clin Exp Optom"},{"issue":"5","key":"10.1016\/j.apjo.2026.100302_bib72","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1167\/iovs.61.5.22","article-title":"Increased Glial Fibrillary Acid Protein and Vimentin in Vitreous Fluid as a Biomarker for Proliferative Vitreoretinopathy","volume":"61","author":"Lee","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1167\/tvst.13.1.3","article-title":"Vitreous Biomarkers for Proliferative Vitreoretinopathy Prognostication in Patients Undergoing Primary Retinal Detachment Repair","volume":"13","author":"Shahlaee","year":"2024","journal-title":"Transl Vis Sci Technol"},{"issue":"10","key":"10.1016\/j.apjo.2026.100302_bib74","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1097\/IAE.0000000000004176","article-title":"MENISCUS MICROPYON: An Ophthalmoscopic Sign Possibly Associated With Epiretinal Proliferation After Retinal Surgery With Gas Tamponade","volume":"44","author":"Russell","year":"2024","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.apjo.2026.100302_bib75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/tvst.13.8.13","article-title":"Postoperative Proliferation Detection in Eyes Treated for Rhegmatogenous Retinal Detachment by WideField OCT Angiography","volume":"13","author":"Fukuda","year":"2024","journal-title":"Transl Vis Sci Technol"},{"issue":"10","key":"10.1016\/j.apjo.2026.100302_bib76","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.oret.2025.04.017","article-title":"Assessment of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment with OCT: Revisiting the 1991 Retina Society Classification","volume":"9","author":"Melo","year":"2025","journal-title":"Ophthalmol Retin"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib77","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.21037\/qims-24-1644","article-title":"Development and validation of the Artificial Intelligence-Proliferative Vitreoretinopathy (AI-PVR) Insight system for deep learning-based diagnosis and postoperative risk prediction in proliferative vitreoretinopathy using multimodal fundus imaging","volume":"15","author":"Gan","year":"2025","journal-title":"Quant Imaging Med Surg"},{"issue":"10","key":"10.1016\/j.apjo.2026.100302_bib78","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1097\/IAE.0000000000000216","article-title":"Pars plana vitrectomy and scleral buckle versus pars plana vitrectomy alone for patients with rhegmatogenous retinal detachment at high risk for proliferative vitreoretinopathy","volume":"34","author":"Storey","year":"2014","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib79","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.oret.2021.10.001","article-title":"Vitrectomy versus Combined Vitrectomy and Scleral Buckle for Repair of Primary Rhegmatogenous Retinal Detachment with Vitreous Hemorrhage","volume":"6","author":"Vangipuram","year":"2022","journal-title":"Ophthalmol Retin"},{"issue":"2","key":"10.1016\/j.apjo.2026.100302_bib80","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10792-015-0104-4","article-title":"Combined pars plana vitrectomy-scleral buckle versus pars plana vitrectomy for proliferative vitreoretinopathy","volume":"36","author":"Lai","year":"2016","journal-title":"Int Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100302_bib81","first-page":"91","article-title":"The Effect of Combining Scleral Buckle Surgery with Pars Plana Vitrectomy for Treatment of Recurrent Retinal Detachment Secondary to Proliferative Vitreoretinopathy","volume":"8","author":"Topcu","year":"2023","journal-title":"Beyoglu Eye J"},{"issue":"8","key":"10.1016\/j.apjo.2026.100302_bib82","doi-asserted-by":"crossref","first-page":"e1749","DOI":"10.1111\/aos.15197","article-title":"Novel insights into the pathophysiology of proliferative vitreoretinopathy: The role of vitreoschisis-induced vitreous cortex remnants","volume":"100","author":"van Overdam","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"10.1016\/j.apjo.2026.100302_bib83","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/aos.16755","article-title":"Vitreoschisis-induced vitreous cortex remnants in proliferative vitreoretinopathy: A comprehensive review from basic research to clinical practice","volume":"102","author":"van Overdam","year":"2024","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib84","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.oret.2019.11.002","article-title":"Intraoperative OCT-Assisted Retinal Detachment Repair in the DISCOVER Study: Impact and Outcomes","volume":"4","author":"Abraham","year":"2020","journal-title":"Ophthalmol Retin"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib85","first-page":"55","article-title":"The outcomes and usefulness of Intraoperative Optical Coherence Tomography in vitreoretinal surgery and its impact on surgical decision making","volume":"66","author":"Zakir","year":"2022","journal-title":"Rom J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100302_bib86","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2147\/OPTH.S4934","article-title":"Relaxing retinotomies and retinectomies in the management of retinal detachment with severe proliferative vitreoretinopathy (PVR)","volume":"4","author":"Shalaby","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100302_bib87","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2474126419831614","article-title":"Outcomes of 25-gauge vitrectomy with relaxing retinectomy for retinal detachment secondary to proliferative vitreoretinopathy","volume":"3","author":"Jiang","year":"2019","journal-title":"J Vitreoretin Dis"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib88","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jfo.2015.09.010","article-title":"Beyond-the-edge proliferation after relaxing retinectomy","volume":"39","author":"Denion","year":"2016","journal-title":"J Fr Ophtalmol"},{"issue":"7","key":"10.1016\/j.apjo.2026.100302_bib89","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/IAE.0000000000002592","article-title":"RECURRENCES OF RETINAL DETACHMENT AFTER RETINECTOMY: Causes and Outcomes","volume":"40","author":"Beuste","year":"2020","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib90","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.tjo.2012.06.002","article-title":"Vitrectomy techniques for complex retinal detachments","volume":"2","author":"Charles","year":"2012","journal-title":"Taiwan J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100302_bib91","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ajo.2021.07.028","article-title":"Drainage Retinotomy Confers Risk of Epiretinal Membrane Formation After Vitrectomy for Rhegmatogenous Retinal Detachment Repair","volume":"234","author":"Ishikawa","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.apjo.2026.100302_bib92","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1097\/IAE.0000000000000593","article-title":"Subretinal Surgery Ab Externo: A Novel Approach to Access the Subretinal Space Without the Need for Retinotomy","volume":"35","author":"Wolff","year":"2015","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.11.4.11","article-title":"Novel Surgical Pathway for Controlled Access to the Subretinal Space: A Case Series","volume":"11","author":"Sabti","year":"2022","journal-title":"Transl Vis Sci Technol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib94","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10384-024-01143-6","article-title":"Assessment of the transscleral removal technique for subretinal proliferative tissues during vitrectomy for rhegmatogenous retinal detachment","volume":"69","author":"Ishibashi","year":"2025","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib95","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12886-022-02449-0","article-title":"Evaluation of Ab externo subretinal bands removal during pars plana vitrectomy for rhegmatogenous retinal detachment complicated by proliferative vitreoretinopathy","volume":"22","author":"Elbaha","year":"2022","journal-title":"BMC Ophthalmol"},{"issue":"9","key":"10.1016\/j.apjo.2026.100302_bib96","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.oret.2022.06.012","article-title":"Post-Retinal Detachment Repair Diffuse Tractional Retinoschisis Sparing Region of Internal Limiting Membrane Peel","volume":"6","author":"Budoff","year":"2022","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.apjo.2026.100302_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2018.03.037","article-title":"Internal Limiting Membrane Peeling in Macula-off Retinal Detachment Complicated by Grade B Proliferative Vitreoretinopathy","volume":"191","author":"Foveau","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100302_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.08.015","article-title":"Internal Limiting Membrane Peeling to Prevent Post-vitrectomy Epiretinal Membrane Development in Retinal Detachment","volume":"171","author":"Akiyama","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib99","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10792-022-02397-0","article-title":"Extensive internal limiting membrane peeling for proliferative vitreoretinopathy","volume":"43","author":"Francone","year":"2023","journal-title":"Int Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/24741264231155352","article-title":"Effect of Macular Internal Limiting Membrane Peeling on Single Surgery Success Rates of Vitrectomy for Uncomplicated, Primary Macula-Off Retinal Detachment","volume":"7","author":"Martens","year":"2023","journal-title":"J Vitreoretin Dis"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib101","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10384-023-01000-y","article-title":"Effects of internal limiting membrane peeling on anatomical and functional outcomes in macula-off rhegmatogenous retinal detachment complicated by proliferative vitreoretinopathy: Japan-Retinal Detachment Registry","volume":"67","author":"Obata","year":"2023","journal-title":"Jpn J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib102","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.oret.2025.06.006","article-title":"Internal Limiting Membrane Peeling for Grade C Proliferative Vitreoretinopathy: An International Multicenter Study","volume":"10","author":"Wakabayashi","year":"2026","journal-title":"Ophthalmol Retin"},{"issue":"11","key":"10.1016\/j.apjo.2026.100302_bib103","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/bjo.2003.040402","article-title":"Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid","volume":"88","author":"Asaria","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib104","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/IAE.0b013e31826a6978","article-title":"Pars plana vitrectomy with medium-term postoperative perfluoro-N-octane for recurrent inferior retinal detachment complicated by advanced proliferative vitreoretinopathy","volume":"33","author":"Sigler","year":"2013","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.apjo.2026.100302_bib105","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.ophtha.2005.04.013","article-title":"Anatomical and functional outcomes after heavy silicone oil tamponade in vitreoretinal surgery for complicated retinal detachment: a pilot study","volume":"112","author":"Tognetto","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.apjo.2026.100302_bib106","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/136031","article-title":"Heavy silicone oil as a long-term endotamponade agent for complicated retinal detachments","volume":"2014","author":"Prazeres","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.apjo.2026.100302_bib107","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/OPTH.S400156","article-title":"Short-Term Total Tamponade with Perfluorocarbon Liquid and Silicone Oil in Complex Rhegmatogenous Retinal Detachment with Severe Proliferative Vitreoretinopathy","volume":"17","author":"Trabelsi","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.apjo.2026.100302_bib108","article-title":"Double Retinal Tamponade for Treatment of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy and Inferior Breaks","volume":"2020","author":"Farouk Abdelkader","year":"2020","journal-title":"J Ophthalmol"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib109","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1055\/s-0042-122384","article-title":"Intraocular Dexamethasone Implant as Adjunct to Silicone Oil Tamponade for Proliferative Vitreoretinopathy","volume":"234","author":"Sherif","year":"2017","journal-title":"Klin Monbl Augenheilkd"},{"issue":"6","key":"10.1016\/j.apjo.2026.100302_bib110","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/IAE.0b013e3181fe5427","article-title":"Midterm results of low-dose intravitreal triamcinolone as adjunctive treatment for proliferative vitreoretinopathy","volume":"31","author":"Chen","year":"2011","journal-title":"Retina"},{"issue":"9","key":"10.1016\/j.apjo.2026.100302_bib111","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/jamaophthalmol.2015.1823","article-title":"Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15","volume":"133","author":"Aref","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.apjo.2026.100302_bib112","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3928\/23258160-20191009-03","article-title":"Erosive Retinopathy and Retinal Detachment From Depot Intravitreal Triamcinolone Acetonide Injection at the End of Pars Plana Vitrectomy","volume":"50","author":"Sisk","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retin"},{"issue":"7","key":"10.1016\/j.apjo.2026.100302_bib113","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s00417-011-1919-y","article-title":"Systemic corticosteroids reduce the risk of cellophane membranes after retinal detachment surgery: a prospective randomized placebo-controlled double-blind clinical trial","volume":"250","author":"Koerner","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"11","key":"10.1016\/j.apjo.2026.100302_bib114","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.ophtha.2008.05.016","article-title":"Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for proliferative vitreoretinopathy: a randomized clinical trial","volume":"115","author":"Ahmadieh","year":"2008","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.apjo.2026.100302_bib115","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.01.021","article-title":"Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial","volume":"124","author":"Banerjee","year":"2017","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.apjo.2026.100302_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/GNBJ1387","article-title":"A randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery for open globe trauma - the ASCOT study","volume":"27","author":"Charteris","year":"2023","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib117","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1136\/bjo-2022-322787","article-title":"Randomised controlled trial of adjunctive triamcinolone acetonide in eyes undergoing vitreoretinal surgery following open globe trauma: The ASCOT study","volume":"108","author":"Casswell","year":"2024","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.apjo.2026.100302_bib118","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1136\/bjo-2023-324318","article-title":"Early use of intravitreal triamcinolone to inhibit traumatic proliferative vitreoretinopathy: a randomised clinical trial","volume":"108","author":"Guo","year":"2024","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.apjo.2026.100302_bib119","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/24741264221076357","article-title":"Systemic and Intraocular Methotrexate for the Prevention and Treatment of Proliferative Vitreoretinopathy in Children With Rhegmatogenous Retinal Detachment and Underlying Inflammatory Disease","volume":"6","author":"Al-Moujahed","year":"2022","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.apjo.2026.100302_bib120","article-title":"Anatomical and Functional Outcomes of Vitrectomy with\/without Intravitreal Methotrexate Infusion for Management of Proliferative Vitreoretinopathy Secondary to Rhegmatogenous Retinal Detachment","volume":"2021","author":"El Baha","year":"2021","journal-title":"J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib121","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/bjh.17451","article-title":"Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience","volume":"194","author":"Habot-Wilner","year":"2021","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.apjo.2026.100302_bib122","doi-asserted-by":"crossref","first-page":"e1070","DOI":"10.1111\/aos.14735","article-title":"Comparative cytotoxic and antiproliferative profile of methotrexate and fluorouracil on different ocular cells","volume":"99","author":"Schulz","year":"2021","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib123","doi-asserted-by":"crossref","first-page":"95","DOI":"10.51329\/mehdiophthal1452","article-title":"Intravitreal methotrexate infusion for prophylaxis of proliferative vitreoretinopathy after pars plana vitrectomy for rhegmatogenous retinal detachment","volume":"11","author":"Fouad Aziz","year":"2022","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib124","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-79708-1","article-title":"Effects of repeated intra-silicone oil injections of methotrexate on proliferative vitreoretinopathy grade C: a multicenter randomized controlled trial","volume":"14","author":"Nourinia","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib125","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2024.10.006","article-title":"A Modified Intravitreal Methotrexate Protocol for the Prevention of Proliferative Vitreoretinopathy after Silicone Oil Removal","volume":"9","author":"Liu","year":"2025","journal-title":"Ophthalmol Retin"},{"key":"10.1016\/j.apjo.2026.100302_bib126","unstructured":"Riemann C.D. Interim Report of the FIXER Trial: Prevention of Proliferative Vitreoretinopathy With Intravitreal Methotrexate in Primary Retinal Detachment Repair. Presented at: ASRS 43rd Annual Scientific Meeting; July 30\u2013August 2, 2025; Long Beach, California (unpublished data)."},{"key":"10.1016\/j.apjo.2026.100302_bib127","unstructured":"Mafi M. Hypotony Rates After Vitrectomy for PVR: Insights on Intravitreal MTX Use. Presented at: ASRS 43rd Annual Scientific Meeting; July 30-August 2, 2025; Long Beach, California (unpublished data)."},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib128","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0002-9394(83)90452-X","article-title":"Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy","volume":"96","author":"Stern","year":"1983","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100302_bib129","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0161-6420(84)34318-4","article-title":"5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite","volume":"91","author":"Blumenkranz","year":"1984","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.apjo.2026.100302_bib130","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0161-6420(01)00589-9","article-title":"Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial","volume":"108","author":"Asaria","year":"2001","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib131","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ophtha.2006.08.042","article-title":"Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy","volume":"114","author":"Wickham","year":"2007","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.apjo.2026.100302_bib132","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ophtha.2022.05.024","article-title":"Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy: Results from a Randomized Clinical Trial","volume":"129","author":"Schaub","year":"2022","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.apjo.2026.100302_bib133","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/bjophthalmol-2016-309134","article-title":"Preoperative aqueous humour flare values do not predict proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment","volume":"101","author":"Mulder","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib134","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12886-024-03362-4","article-title":"Efficacy of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) in high-risk pediatric retinal detachment; randomized clinical trial","volume":"24","author":"Nasr","year":"2024","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"10.1016\/j.apjo.2026.100302_bib135","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0002-9394(02)01406-X","article-title":"Inverse levels of pigment epithelium-derived factor and vascular endothelial growth factor in the vitreous of eyes with rhegmatogenous retinal detachment and proliferative vitreoretinopathy","volume":"133","author":"Ogata","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib136","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/IAE.0b013e31821800b9","article-title":"Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy","volume":"32","author":"Ricker","year":"2012","journal-title":"Retina"},{"issue":"6","key":"10.1016\/j.apjo.2026.100302_bib137","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3109\/02713681003597248","article-title":"Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment","volume":"35","author":"Rasier","year":"2010","journal-title":"Curr Eye Res"},{"issue":"5","key":"10.1016\/j.apjo.2026.100302_bib138","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/eye.2014.21","article-title":"Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy","volume":"28","author":"Ghasemi Falavarjani","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.apjo.2026.100302_bib139","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2015.09.029","article-title":"Effect of Serial Intrasilicone Oil Bevacizumab Injections in Eyes With Recurrent Proliferative Vitreoretinopathy Retinal Detachment","volume":"161","author":"Hsu","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"12","key":"10.1016\/j.apjo.2026.100302_bib140","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/eye.2014.198","article-title":"Comment on 'Intrasilicone oil injection of bevacizumab at the end of retinal reattachment surgery for severe proliferative vitreoretinopathy'","volume":"28","author":"Radke","year":"2014","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-240506","article-title":"Tractional retinal detachment ('crunch' phenomenon) from intravitreal anti-vascular endothelial growth factor injection in central retinal vein occlusion","volume":"14","author":"Bromeo","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib142","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1167\/iovs.65.4.37","article-title":"Short Term Effect of Pre-Operative Anti-VEGF on Angiogenic and Fibrotic Profile of Fibrovascular Membranes of Proliferative Diabetic Retinopathy","volume":"65","author":"Fadakar","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib143","first-page":"65","article-title":"Retinoic acid promotes density-dependent growth arrest in human retinal pigment epithelial cells","volume":"32","author":"Campochiaro","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.apjo.2026.100302_bib144","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1089\/jop.2005.21.44","article-title":"Effects of retinoic acid on retinal pigment epithelium from excised membranes from proliferative vitreoretinopathy","volume":"21","author":"Wu","year":"2005","journal-title":"J Ocul Pharm Ther"},{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib145","first-page":"522","article-title":"Antiproliferative effect of retinoic acid in intravitreous silicone oil in an animal model of proliferative vitreoretinopathy","volume":"34","author":"Araiz","year":"1993","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib146","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/exer.1997.0355","article-title":"13-cis-retinoic acid in silicone-fluorosilicone copolymer oil in a rabbit model of proliferative vitreoretinopathy","volume":"65","author":"Veloso","year":"1997","journal-title":"Exp Eye Res"},{"issue":"12","key":"10.1016\/j.apjo.2026.100302_bib147","first-page":"2388","article-title":"Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy","volume":"36","author":"Nakagawa","year":"1995","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib148","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0161-6420(95)31007-X","article-title":"The effect of oral 13-cis-retinoic acid on retinal redetachment after surgical repair in eyes with proliferative vitreoretinopathy","volume":"102","author":"Fekrat","year":"1995","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.apjo.2026.100302_bib149","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ajo.2008.05.002","article-title":"Effect of oral 13-cis-retinoic acid treatment on postoperative clinical outcome of eyes with proliferative vitreoretinopathy","volume":"146","author":"Chang","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.apjo.2026.100302_bib150","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/bjophthalmol-2018-312839","article-title":"Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial","volume":"103","author":"London","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.apjo.2026.100302_bib151","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.oret.2024.05.016","article-title":"Intravitreal Infliximab for the Treatment of Proliferative Vitreoretinopathy (FIXER): A Randomized Controlled Phase II Trial","volume":"8","author":"Younes","year":"2024","journal-title":"Ophthalmol Retin"},{"issue":"5","key":"10.1016\/j.apjo.2026.100302_bib152","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1001\/archopht.125.5.647","article-title":"Effect of Smad7 gene overexpression on transforming growth factor beta-induced retinal pigment fibrosis in a proliferative vitreoretinopathy mouse model","volume":"125","author":"Saika","year":"2007","journal-title":"Arch Ophthalmol"},{"issue":"6281","key":"10.1016\/j.apjo.2026.100302_bib153","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/346281a0","article-title":"Negative regulation of transforming growth factor-beta by the proteoglycan decorin","volume":"346","author":"Yamaguchi","year":"1990","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.apjo.2026.100302_bib154","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.matbio.2010.01.001","article-title":"The role of small leucine-rich proteoglycans in collagen fibrillogenesis","volume":"29","author":"Kalamajski","year":"2010","journal-title":"Matrix Biol"},{"issue":"12","key":"10.1016\/j.apjo.2026.100302_bib155","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1007\/s00417-018-4105-7","article-title":"Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study","volume":"256","author":"Abdullatif","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"10.1016\/j.apjo.2026.100302_bib156","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1167\/iovs.12-10418","article-title":"Inhibition of PVR with a tyrosine kinase inhibitor, dasatinib, in the swine","volume":"54","author":"Umazume","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"15","key":"10.1016\/j.apjo.2026.100302_bib157","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26157131","article-title":"Nintedanib Induces Mesenchymal-to-Epithelial Transition and Reduces Subretinal Fibrosis Through Metabolic Reprogramming","volume":"26","author":"Hughes","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["Asia-Pacific Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926000289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162098926000289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T04:07:43Z","timestamp":1775448463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162098926000289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":157,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2162098926000289"],"URL":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100302","relation":{},"ISSN":["2162-0989"],"issn-type":[{"value":"2162-0989","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing perspectives on proliferative vitreoretinopathy: Updates in experimental research and emerging clinical treatments","name":"articletitle","label":"Article Title"},{"value":"Asia-Pacific Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apjo.2026.100302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Asia-Pacific Academy of Ophthalmology and Academy of Asia-Pacific Professors of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100302"}}